Work

Ribavirin Treatment in Acute HEV-Induced Liver Injury in a Healthy US Female: A Case Report

Year: 2025

Type: article

Abstract: Introduction: Hepatitis E virus (HEV) is a global cause of acute viral hepatitis, for which there is currently no FDA-approved medication. This case report describes a unique instance of a healthy US female presenting with acute HEV, who was treated with ribavirin to address her acute liver injury. Case Presentation: A 36-year-old US female, nonpregnant, without liver disease, developed nonspecific symptoms post-travel to Indonesia, leading to acute liver injury with concern for failure. Liver biopsy showed severe hepatocellular necrosis (>50%) with mixed infiltrate; HEV PCR was positive (93,700,000 IU/mL) [Am J Gastroenterol. 2024;119(10S):S2872-3]. After risk-benefit analysis, ribavirin treatment resolved symptoms and normalized biomarkers in a month, avoiding emergency transplantation. Conclusion: HEV infection should be considered in acute liver injury cases in the US, especially with exposure risks. Ribavirin's role in acute cases warrants further study, potentially averting major morbidity and mortality.

Source: Case Reports in Gastroenterology

DOI: 10.1159/000546235

Authors: Nadera Altork, Michele P. Fischer, Lukman Cheraghvandi, Arul M. Thomas

Institutions: Washington Hospital, MedStar Georgetown University Hospital, Georgetown University Medical Center

Language: English

Topic: Hepatitis Viruses Studies and Epidemiology

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,030